2022
Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data
Mansoor R, Commons R, Douglas N, Abuaku B, Achan J, Adam I, Adjei G, Adjuik M, Alemayehu B, Allan R, Allen E, Anvikar A, Arinaitwe E, Ashley E, Ashurst H, Asih P, Bakyaita N, Barennes H, Barnes K, Basco L, Bassat Q, Baudin E, Bell D, Bethell D, Bjorkman A, Boulton C, Bousema T, Brasseur P, Bukirwa H, Burrow R, Carrara V, Cot M, D’Alessandro U, Das D, Das S, Davis T, Desai M, Djimde A, Dondorp A, Dorsey G, Drakeley C, Duparc S, Espié E, Etard J, Falade C, Faucher J, Filler S, Fogg C, Fukuda M, Gaye O, Genton B, Rahim A, Gilayeneh J, Gonzalez R, Grais R, Grandesso F, Greenwood B, Grivoyannis A, Hatz C, Hodel E, Humphreys G, Hwang J, Ishengoma D, Juma E, Kachur S, Kager P, Kamugisha E, Kamya M, Karema C, Kayentao K, Kazienga A, Kiechel J, Kofoed P, Koram K, Kremsner P, Lalloo D, Laman M, Lee S, Lell B, Maiga A, Mårtensson A, Mayxay M, Mbacham W, McGready R, Menan H, Ménard D, Mockenhaupt F, Moore B, Müller O, Nahum A, Ndiaye J, Newton P, Ngasala B, Nikiema F, Nji A, Noedl H, Nosten F, Ogutu B, Ojurongbe O, Osorio L, Ouédraogo J, Owusu-Agyei S, Pareek A, Penali L, Piola P, Plucinski M, Premji Z, Ramharter M, Richmond C, Rombo L, Roper C, Rosenthal P, Salman S, Same-Ekobo A, Sibley C, Sirima S, Smithuis F, Somé F, Staedke S, Starzengruber P, Strub-Wourgaft N, Sutanto I, Swarthout T, Syafruddin D, Talisuna A, Taylor W, Temu E, Thwing J, Tinto H, Tjitra E, Touré O, Tran T, Ursing J, Valea I, Valentini G, van Vugt M, von Seidlein L, Ward S, Were V, White N, Woodrow C, Yavo W, Yeka A, Zongo I, Simpson J, Guerin P, Stepniewska K, Price R. Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. BMC Medicine 2022, 20: 85. PMID: 35249546, PMCID: PMC8900374, DOI: 10.1186/s12916-022-02265-9.Peer-Reviewed Original ResearchConceptsUncomplicated P. falciparum malariaSevere anemiaDay 7Nadir hemoglobinParasite clearanceTreatment of uncomplicated P. falciparum malariaDay 3Risk factorsHaematological responseRate of parasite clearanceWorldWide Antimalarial Resistance NetworkArtemisinin-based regimensBackgroundPlasmodium falciparum malariaDelayed parasite clearanceMethodsIndividual patient dataMedian hemoglobin concentrationIndependent risk factorRisk of anemiaArtemisinin-based treatmentsDay 2 post treatmentDay of nadirModerately severe anemiaIndividual patient dataPatient dataMalarial anemia
2017
Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis
Hoglund RM, Workman L, Edstein MD, Thanh NX, Quang NN, Zongo I, Ouedraogo JB, Borrmann S, Mwai L, Nsanzabana C, Price RN, Dahal P, Sambol NC, Parikh S, Nosten F, Ashley EA, Phyo AP, Lwin KM, McGready R, Day NP, Guerin PJ, White NJ, Barnes KI, Tarning J. Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLOS Medicine 2017, 14: e1002212. PMID: 28072872, PMCID: PMC5224788, DOI: 10.1371/journal.pmed.1002212.Peer-Reviewed Original ResearchConceptsPiperaquine exposureDose regimenFalciparum malariaSmall childrenLarger childrenDay 7 plasma concentrationsThree-compartment disposition modelUncomplicated Plasmodium falciparum malariaNonlinear mixed-effects modellingPopulation pharmacokinetic propertiesIndividual Participant Data Meta-AnalysisPlasmodium falciparum malariaPopulation pharmacokinetic modelData Meta-AnalysisGuideline development groupUseful therapeutic lifeYoung childrenWorldWide Antimalarial Resistance NetworkConcentration-time dataWorld Health OrganizationDose occasionPiperaquine pharmacokineticsMixed-effects modellingUncomplicated malariaDose regimens
2014
Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine
Venkatesan M, Gadalla N, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price R, Mårtensson A, Rosenthal P, Dorsey G, Sutherland C, Guérin P, Davis T, Ménard D, Adam I, Ademowo G, Arze C, Baliraine F, Berens-Riha N, Björkman A, Borrmann S, Checchi F, Desai M, Dhorda M, Djimdé A, El-Sayed B, Eshetu T, Eyase F, Falade C, Faucher J, Fröberg G, Grivoyannis A, Hamour S, Houzé S, Johnson J, Kamugisha E, Kariuki S, Kiechel J, Kironde F, Kofoed P, LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsobya S, Nzila A, Oguike M, Otienoburu S, Ogutu B, Ouédraogo J, Piola P, Rombo L, Schramm B, Somé A, Thwing J, Ursing J, Wong R, Zeynudin A, Zongo I, Plowe C, Sibley C, Asaq Molecular Marker Study Group. Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal Of Tropical Medicine And Hygiene 2014, 91: 833-843. PMID: 25048375, PMCID: PMC4183414, DOI: 10.4269/ajtmh.14-0031.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAmodiaquineAntimalarialsArtemetherArtemisininsChildChild, PreschoolChloroquineDatasets as TopicDrug CombinationsDrug ResistanceDrug Therapy, CombinationEthanolaminesFluorenesGenetic MarkersGenotypeHumansInfantKaplan-Meier EstimateLumefantrineMalaria, FalciparumMembrane Transport ProteinsMultidrug Resistance-Associated ProteinsPlasmodium falciparumPolymorphism, GeneticProtozoan ProteinsRisk FactorsConceptsArtemether-lumefantrineP. falciparum multidrug resistance 1 genePlasmodium falciparum chloroquine resistance transporterPfmdr1 copy numberArtemisinin combination therapyIndividual patient dataChloroquine resistance transporterMultidrug resistance 1 geneWorldWide Antimalarial Resistance NetworkParasitologic cureCombination therapyParasite polymorphismsPartner drugsTherapeutic responseClinical trialsRelevant outcomesArtemisinin componentPatient dataResistance transporterStandardized methodPolymorphismPatientsPfmdr1PfcrtAmodiaquine